Pareto Securities Healthcare Conference: Basilea is using its financial strength from two marketed products to develop its pipeline and acquire new products - it just received more BARDA funding today
CEO David Veitch walks us through the U.S. launch of Zevtera, and discusses where Cresemba is in its global commercial lifecycle. Plus, pipeline progress, and how Basilea's experience with BARDA funding has been a good sign of consistency for the field.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.